卵巢癌患者外周血sHLA-G表达水平及临床意义  

Expression of SHLA-G in peripheral blood of patients with ovarian cancer and its clinical significance

作　　者：周李宁 陈彤[1] 陈相[1] 洪宏 赵枰[1] ZHOU Lining;CHEN Tong;CHEN Xiang;HONG Hong;ZHAO Ping(Department of Clinical Laboratory,Nantong First People′s Hospital,Nantong,Jiangsu 226001,China;Department of Clinical Laboratory,Nantong Hospital of Traditional Chinese Medicine,Nantong,Jiangsu 226000,China)

机构地区：[1]江苏省南通市第一人民医院检验科,江苏南通226001 [2]江苏省南通市中医院检验科,江苏南通226000

出　　处：《检验医学与临床》2022年第3期309-312,共4页Laboratory Medicine and Clinic

摘　　要：目的探讨卵巢癌患者外周血(血浆及外泌体)可溶性人类白细胞抗原G(sHLA-G)水平并分析其临床意义。方法收集2018年1月至2020年12月南通市第一人民医院收治的75例患者的临床资料,其中卵巢癌患者41例(卵巢癌组),卵巢良性肿瘤患者34例(卵巢良性肿瘤组),并收集同期健康体检女性30例(健康对照组)的体检资料。采用流式细胞术(FCM)检测各组外泌体sHLA-G阳性占比,采用酶联免疫吸附试验(ELISA)检测血浆sHLA-G水平,采用Spearman相关分析外泌体sHLA-G与血浆sHLA-G的关系。结果FCM法检测显示,卵巢癌组外泌体sHLA-G阳性占比[(73.8±14.7)%]显著高于卵巢良性肿瘤组[(45.8±11.2)%]和健康对照组[(42.9±9.3)%],差异均有统计学意义(P<0.01)。ELISA检测结果显示,卵巢癌组血浆sHLA-G水平[118.7(80.3,163.4)U/mL]显著高于卵巢良性肿瘤组[44.3(36.6,51.4)U/mL]和健康对照组[41.7(30.6,47.8)U/mL],差异均有统计学意义(P<0.01)。不同病理分期卵巢癌患者外泌体sHLA-G阳性占比及不同病理分化程度期卵巢癌患者血浆sHLA-G水平比较,差异均有统计学意义(P<0.05);外泌体sHLA-G与血浆sHLA-G无相关性(r=0.321,P>0.05)。结论卵巢癌患者外周血sHLA-G水平均升高,可作为卵巢癌诊断的潜在肿瘤标志物。Objective To investigate the expression level of soluble human leukocyte antigen G(sHLA-G)in peripheral blood(plasma and exosome)of patients with ovarian cancer and and to evaluate its clinical significance.Methods The clinical data of 75 patients admitted to Nantong First People′s Hospital from January 2018 to December 2020 were collected,including 41 patients with ovarian cancer(ovarian cancer group),34 patients with ovarian benign tumor(ovarian benign tumor group),and 30 healthy females(healthy control group)during the same period.Flow cytometry(FCM)was used to detect the positive proportion of exosome sHLA-G in each group,and the plasma sHLA-G level was detected by enzyme-linked immunosorbent assay(ELISA).Spearman correlation was used to analyze the relationship between exosome sHLA-G and plasma sHLA-G.Results FCM detection ELISA results showed that the positive rate of exosome sHLA-G in the ovarian cancer group[(73.8±14.7)%]was significantly higher than that in the benign ovarian tumor group[(45.8±11.2)%]and healthy control group[(42.9±9.3)%],the differences were statistically significant(P<0.01).ELISA ELISA results showed that plasma sHLA-G level in the ovarian cancer group[118.7(80.3,163.4)U/mL]was significantly higher than that in the benign ovarian cancer group[44.3(36.6,51.4)U/mL]and healthy control group[41.7(30.6,47.8)U/mL],the differences were statistically significant(P<0.01).There were statistically significant differences in the percentage of sHLA-G positive in exosomes of ovarian cancer patients with different pathological stages and the level of sHLA-G in plasma of ovarian cancer patients with different pathological stages(P<0.05).There was no correlation between exosome sHLA-G and plasma sHLA-G(r=0.321,P>0.05).Conclusion The level of sHLA-G in peripheral blood of patients with ovarian cancer is elevated,which can be used as a potential tumor marker in the diagnosis of ovarian cancer.

关 键 词：卵巢肿瘤 外泌体 可溶性人类白细胞抗原G 流式细胞术 

分 类 号：R737.31[医药卫生—肿瘤]